JP2017511365A5 - - Google Patents

Download PDF

Info

Publication number
JP2017511365A5
JP2017511365A5 JP2016562835A JP2016562835A JP2017511365A5 JP 2017511365 A5 JP2017511365 A5 JP 2017511365A5 JP 2016562835 A JP2016562835 A JP 2016562835A JP 2016562835 A JP2016562835 A JP 2016562835A JP 2017511365 A5 JP2017511365 A5 JP 2017511365A5
Authority
JP
Japan
Prior art keywords
triazolo
optionally substituted
amino
pyrazin
pyrazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016562835A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017511365A (ja
Filing date
Publication date
Priority claimed from PCT/CN2014/075560 external-priority patent/WO2015157955A1/en
Application filed filed Critical
Publication of JP2017511365A publication Critical patent/JP2017511365A/ja
Publication of JP2017511365A5 publication Critical patent/JP2017511365A5/ja
Pending legal-status Critical Current

Links

JP2016562835A 2014-04-17 2015-04-16 複素環キナーゼ阻害薬 Pending JP2017511365A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2014/075560 WO2015157955A1 (en) 2014-04-17 2014-04-17 Heterocyclic btk inhibit ors
CNPCT/CN2014/075560 2014-04-17
PCT/CN2015/076766 WO2015158283A1 (en) 2014-04-17 2015-04-16 Heterocyclic kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2017511365A JP2017511365A (ja) 2017-04-20
JP2017511365A5 true JP2017511365A5 (enExample) 2018-05-31

Family

ID=54323386

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016562835A Pending JP2017511365A (ja) 2014-04-17 2015-04-16 複素環キナーゼ阻害薬

Country Status (9)

Country Link
US (2) US10280184B2 (enExample)
EP (1) EP3131900A4 (enExample)
JP (1) JP2017511365A (enExample)
CN (1) CN106459045A (enExample)
AU (1) AU2015246482A1 (enExample)
BR (1) BR112016024057A2 (enExample)
CA (1) CA2946036A1 (enExample)
MX (1) MX2016013564A (enExample)
WO (2) WO2015157955A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9932340B2 (en) * 2014-12-18 2018-04-03 Abbvie Inc. Substituted indoles
JP2018515524A (ja) * 2015-05-12 2018-06-14 カリーラ ファーマシューティカルズ,インク. 二環式化合物
SG11201804210XA (en) * 2015-11-20 2018-06-28 Mingsight Pharmaceuticals Inc Treatment of autoimmune disease
CN108884068B (zh) * 2016-03-24 2021-02-26 特殊治疗有限公司 作为dub抑制剂的1-氰基-吡咯烷衍生物
GB201616511D0 (en) 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
DK3548033T3 (da) 2016-11-28 2024-07-15 Praxis Prec Medicines Inc Forbindelser og deres fremgangsmåde til anvendelse
US11261188B2 (en) 2016-11-28 2022-03-01 Praxis Precision Medicines, Inc. Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel
WO2018148745A1 (en) 2017-02-13 2018-08-16 Praxis Precision Medicines , Inc. Compounds and their methods of use
WO2018175512A1 (en) * 2017-03-22 2018-09-27 Suzhou Baijibugong Pharmaceutical Technology Co. Ltd. Bruton's tyrosine kinase inhibitors
US11731966B2 (en) 2017-04-04 2023-08-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
WO2019035951A1 (en) 2017-08-15 2019-02-21 Praxis Precision Medicines, Inc. COMPOUNDS AND THEIR METHODS OF USE
MA52422A (fr) 2018-02-27 2021-01-06 Incyte Corp Imidazopyrimidines et triazolopyrimidines en tant qu'inhibiteurs a2a/a2b
MX2020012376A (es) 2018-05-18 2021-03-09 Incyte Corp Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b.
EP3801535A4 (en) 2018-05-30 2022-03-02 Praxis Precision Medicines, Inc. ION CHANNEL MODULATORS
MA53097A (fr) * 2018-07-05 2021-05-12 Incyte Corp Dérivés de pyrazine fusionnés en tant qu'inhibiteurs d'a2a/a2b
EA202092908A1 (ru) 2018-09-28 2021-05-14 Праксис Пресижн Медсинз, Инк. Модуляторы ионных каналов
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
US11773099B2 (en) 2019-05-28 2023-10-03 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11279700B2 (en) 2019-05-31 2022-03-22 Praxis Precision Medicines, Inc. Ion channel modulators
US11505554B2 (en) 2019-05-31 2022-11-22 Praxis Precision Medicines, Inc. Substituted pyridines as ion channel modulators
WO2021040502A1 (ko) * 2019-08-30 2021-03-04 주식회사 티에스디라이프사이언스 이미다조피리딘 유도체 및 이를 유효성분으로 함유하는 약학적 조성물
US11767325B2 (en) 2019-11-26 2023-09-26 Praxis Precision Medicines, Inc. Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators
EP3915990A1 (en) 2020-05-26 2021-12-01 Centre National de la Recherche Scientifique 4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridine-1-(2h)-carboxamide derivatives as limk and/or rock kinases inhibitors for use in the treatment of cancer
JP7535600B2 (ja) * 2020-06-01 2024-08-16 ナンジン ルイジエ ファーマ シーオー.,エルティーディー. 化合物および脾臓チロシンキナーゼ阻害剤としてのその使用
TW202214634A (zh) * 2020-06-09 2022-04-16 大陸商賽諾哈勃藥業(成都)有限公司 雜環化合物及其衍生物
GB202014114D0 (en) * 2020-09-08 2020-10-21 Synairgen Res Ltd Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid
KR20230119134A (ko) * 2020-11-13 2023-08-16 바이오젠 엠에이 인코포레이티드 Btk 저해제로서의 피라졸로[1,5-a]피라진 유도체
JP2025515728A (ja) * 2022-05-10 2025-05-20 バイオジェン・エムエイ・インコーポレイテッド N-メチル-N-((1s,3s)-3-メチル-3-((6-(1-メチル-1H-ピラゾール-4-イル)ピラゾロ[1,5-a]ピラジン-4-イル)オキシ)シクロブチル)アクリルアミドの結晶多形

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002060492A1 (en) * 2001-01-30 2002-08-08 Cytopia Pty Ltd Methods of inhibiting kinases
PL363959A1 (en) * 2001-03-09 2004-11-29 Pfizer Products Inc. Triazolopyridines as anti-inflammatory agents
WO2005014599A1 (en) * 2003-06-04 2005-02-17 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
WO2005085252A1 (en) * 2004-03-04 2005-09-15 Biofocus Discovery Limited Imidazo ‘1,2-a’ pyrazine compounds which interact with protein kinases
DE102004030782A1 (de) * 2004-06-25 2006-01-19 Fev Motorentechnik Gmbh Fahrzeug-Steuergerät mit einem neuronalen Netz
EP1812439B2 (en) * 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
US7700773B2 (en) * 2005-09-09 2010-04-20 Schering Corporation 4-cyano, 4-amino, and 4-aminomethyl derivatives of pyrazolo[1,5-a]pyridines, pyrazolo[1,5-c]pyrimidines and 2H-indazole compounds and 5-cyano, 5-amino, and 5-aminomethyl derivatives of imidazo[1,2-a]pyridines, and imidazo[1,5-a]pyrazines as cyclin dependent kinase inhibitors
DE102007032349A1 (de) 2007-07-11 2009-01-15 Bayer Healthcare Ag Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung
PE20091074A1 (es) 2007-12-13 2009-07-26 Bayer Healthcare Ag Triazolotriazinas y triazolopirazinas y su uso
CN101952283B (zh) 2007-12-14 2013-04-17 霍夫曼-拉罗奇有限公司 咪唑并[1,2-a]吡啶和咪唑并[1,2-b]哒嗪衍生物
EP2307413B1 (en) 2008-07-15 2015-09-09 F. Hoffmann-La Roche AG Novel phenyl-imidazopyridines and pyridazines
TWI453207B (zh) * 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶,其組合物及使用其之治療方法
MX2011006094A (es) 2008-12-08 2011-11-29 Gilead Connecticut Inc Inhibidores de imidazopirazina syk.
WO2010068806A1 (en) 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer
WO2010068810A2 (en) * 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
EP2343294A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
BR112012022943A2 (pt) 2010-03-11 2018-06-05 Gilead Connecticut Inc inibidores de syk de imidazopiridnas
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
WO2012080230A1 (en) * 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
CA2832310A1 (en) * 2011-04-06 2012-10-11 Bayer Intellectual Property Gmbh Substituted imidazopyridines and intermediates thereof
WO2012163724A1 (en) * 2011-05-31 2012-12-06 F. Hoffmann-La Roche Ag Triazolopyridine compounds
JP6173327B2 (ja) 2011-11-01 2017-08-02 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト イミダゾピリダジン化合物
ES2552514T3 (es) 2011-11-03 2015-11-30 Hoffmann-La Roche Ag Compuestos bicíclicos de piperazina
JP5832664B2 (ja) * 2011-12-09 2015-12-16 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft ブルトン型チロシンキナーゼの阻害剤

Similar Documents

Publication Publication Date Title
JP2017511365A5 (enExample)
JP7323723B2 (ja) Nav1.8阻害剤としての2-オキソイミダゾリジン-4-カルボキサミド
JP7398391B2 (ja) N-[4-オキソ-2,3-ジヒドロ-1,5-ベンズオキサゼピン-3-イル]-5,6-ジヒドロ-4H-ピロロ[1,2-b]ピラゾール-2-カルボキサミド誘導体及び例えば過敏性腸症候群(IBS)を処置するためのRIP1キナーゼ阻害剤としての関連化合物
US9617258B2 (en) Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
HRP20201641T1 (hr) Novi spojevi i njihove farmaceutske kompozicije za liječenje inflamatornih poremećaja
RU2019115115A (ru) Производные пиперидина в качестве ингибиторов убиквитин-специфической протеазы 7
EP2582703A1 (en) Heteroaryl imidazolone derivatives as jak inhibitors
RU2009136299A (ru) Новые производные 3-({1,2,4}триазоло{4,3-а}пиридин-7-ил)бензамида
TW201725202A (zh) 新穎經取代吲唑、其製法、包含其之醫藥製劑及其製備藥劑之用途
US9040534B2 (en) [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
JP2013539762A (ja) フロ[3,2−d]ピリミジン化合物
JP2020526549A5 (enExample)
JP2017193592A5 (enExample)
SI3083625T1 (en) Pyrimidopyrimidinones, useful as Wee-1 kinase inhibitors
JP2017511365A (ja) 複素環キナーゼ阻害薬
JP2013533868A (ja) タンパク質チロシンキナーゼ阻害剤としての新規ホモピペラジン誘導体およびそれらの医薬使用
JP2017531672A5 (enExample)
JP2020536915A5 (enExample)
JP2017501177A5 (enExample)
JPWO2021113479A5 (enExample)
JPWO2021224636A5 (enExample)
JPWO2023064366A5 (enExample)
JPWO2020207991A5 (enExample)
JPWO2023067355A5 (enExample)
WO2024052513A1 (en) Heterocyclic derivatives as janus kinase inhibitors